Abbreviation · Organisation
GIDS
Gender Identity Development Service — the British youth gender clinic at Tavistock, closed in 2024.
2 min read · updated May 2026
GIDS was from 1989 to 2024 the only NHS clinic for young people with gender dysphoria in England and Wales, housed within the Tavistock and Portman NHS Trust in London. The clinic prescribed puberty blockers and cross-sex hormones to young people from the age of 11.
In 2022, the interim Cass Review found that GIDS did not meet clinical standards. The NHS closed GIDS in 2024 following the final report of the Cass Review. Former clinicians such as psychologist Sonia Appleby and paediatrician Hilary Cass have publicly criticised the clinic's practices.
Critical Analysis
GIDS is, in retrospect, the textbook example of what happens when activism takes the place of clinical rigour: minimal screening, a single treatment pathway, no long-term follow-up, no investigation of co-occurring conditions. Hundreds of former patients — now detransitioners — have stated that they were pushed by GIDS into an irreversible pathway without alternatives being offered. The Cass Review documents this systematically.
Related
Political Function of the Abbreviation
An abbreviation like GIDS is not a linguistic invention but a political instrument. Those who use the abbreviation simultaneously signal acceptance of the accompanying ideological framework: identity over biology, self-declaration over diagnosis, language over reality. Those who refuse to go along are accused of being outdated or hateful.
Resistance to that pressure does not come only from conservative quarters. Lesbian organisations, sports federations, women's rights organisations and clinicians are objecting to the shifting of category boundaries. The abbreviation itself is often defended on the grounds of inclusion, but in practice it compels the abandonment of categories that are precisely protective — for women, for lesbians, for children.
Medical Context and the Evidence
The medical side of the debate has shifted entirely within the space of a few years. The Cass Review (2024) found that the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England consequently ceased routine prescribing. SBU (Sweden, 2022), COHERE (Finland, 2020), UKOM (Norway, 2023) and NICE (UK, 2020) reached the same conclusion.
In the communications of organisations that embrace GIDS and related terms, those reassessments are almost always absent. The impression of a settled science is maintained by silence about the Cass Review and the Scandinavian reversal. The WPATH Files (2024) revealed that even within WPATH, clinicians harbour uncertainty about informed consent in minors.
Consequences for Public Debate
Expanding abbreviations is not cost-free. Every new letter comes with a claim to recognition in legislation, education and healthcare. Without evidence for the underlying category, policy is made as though the evidence exists. Those who ask questions receive not substantive answers but moral condemnation.
Language drives policy. To accept the abbreviation is to implicitly accept the claim that all the identities it encompasses are equivalent and scientifically grounded. That is a political claim, not a linguistic one. Criticism of an abbreviation is not criticism of individuals — it is criticism of a framework that is being placed ever further beyond the reach of debate.
International Reassessment
Several national health authorities have in recent years distanced themselves from the gender-affirming model for minors. The common denominator: evidence for lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of a research setting.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and the Karolinska University Hospital stopped prescribing puberty blockers and hormones to minors outside of a research setting. Reason: evidence for effectiveness and safety is lacking.
NICE — United Kingdom (2020). Two evidence reviews by NICE (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised the protocol: psychotherapy as first-line treatment, medical transition in minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified gender-affirming care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians reveal acknowledgement that informed consent in minors is problematic and that serious side effects (bone density, fertility, cognitive development) are inadequately explained.